DNA Methylation Clocks Reveal Which Aging Biomarkers Best Predict Frailty Risk
Meta-analysis of 28,000+ people shows GrimAge epigenetic clock consistently predicts frailty better than other DNA methylation aging measures.
Summary
Researchers analyzed 24 studies involving over 28,000 participants to determine which DNA methylation-based aging biomarkers best predict frailty. While basic DNA methylation age showed no association with frailty, several epigenetic age acceleration (EAA) measures did. GrimAge EAA emerged as the most reliable predictor, showing consistent associations with frailty in both cross-sectional and longitudinal analyses. Other measures like Hannum EAA, PhenoAge EAA, and pace of aging showed associations only in cross-sectional studies. This research helps identify which molecular aging clocks are most clinically useful for predicting age-related decline.
Detailed Summary
This comprehensive meta-analysis addresses a critical question in aging research: which DNA methylation-based biomarkers best predict frailty, a condition characterized by multisystem decline that increases vulnerability to adverse health outcomes.
Researchers systematically reviewed 24 studies encompassing 28,325 participants (median age 65.2 years, 52.1% female) to examine associations between various DNA methylation aging metrics and frailty. They analyzed basic DNA methylation age, epigenetic age acceleration (EAA) measures, and age deviation across multiple epigenetic clocks.
The results revealed important distinctions between different aging biomarkers. While basic DNA methylation age showed no association with frailty, several EAA measures demonstrated significant relationships. In cross-sectional analyses, higher Hannum EAA, PhenoAge EAA, GrimAge EAA, and pace of aging were all associated with increased frailty. However, longitudinal analysis revealed that only GrimAge EAA maintained a significant association with frailty progression over time.
These findings have important implications for clinical practice and aging research. GrimAge EAA's consistent performance across both cross-sectional and longitudinal analyses suggests it may be the most reliable epigenetic biomarker for identifying individuals at risk of frailty. This could enable earlier interventions and better risk stratification in clinical settings.
However, the study has limitations including high heterogeneity between studies and the need for larger, harmonized longitudinal cohorts to validate these findings for clinical translation.
Key Findings
- GrimAge epigenetic age acceleration consistently predicted frailty in both cross-sectional and longitudinal analyses
- Basic DNA methylation age showed no association with frailty across all studies
- Hannum, PhenoAge EAA, and pace of aging predicted frailty only cross-sectionally, not longitudinally
- Meta-analysis included 28,325 participants across 24 studies with median age 65.2 years
- High study heterogeneity suggests need for standardized frailty assessment methods
Methodology
Systematic review and meta-analysis of 24 population-based cohort studies from six databases (2011-2025). Used random-effects meta-analyses with Hartung-Knapp adjustments on standardized β coefficients, including both cross-sectional and longitudinal study designs.
Study Limitations
High heterogeneity between studies (I2 values 71-91%) suggests methodological differences. Limited longitudinal data and need for larger, harmonized cohorts before clinical translation. Frailty assessment methods varied across studies, potentially affecting comparability.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.